Baptist Health South Florida

Scholarly Commons @ Baptist Health South Florida
All Publications
2019

First-in-Human Experience With Integration of a Hydrocephalus
Shunt Device Within a Customized Cranial Implant
Frank Vrionis
Boca Raton Regional Hospital; Marcus Neuroscience Institute; BocaCare® Physician Network,
fvrionis@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications

Citation
Oper Neurosurg (Hagerstown) (2019) 17(6):608-615

This Article -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health
South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly
Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.

CONCEPTS, INNOVATIONS AND TECHNIQUES
Chad R. Gordon, DO∗ ‡
Amir Wolff, DMD∗ ‡
Gabriel F. Santiago, MD∗ ‡
Kenneth Liebman, MD§ ||
Erol Veznedaroglu, MD§ ||
Frank D. Vrionis, MD, MPH,

First-in-Human Experience With Integration of a
Hydrocephalus Shunt Device Within a Customized
Cranial Implant

PhD¶
‡

Judy Huang, MD
‡

Henry Brem, MD

Mark Luciano, MD, PhD‡
∗
Division of Neuroplastic and Reconstructive Surgery, Department of Plastic
and Reconstructive Surgery, Surgery,
Department of Plastic and Reconstructive
Surgery, Johns Hopkins University
School of Medicine, The Johns Hopkins
Hospital, Baltimore, Maryland; ‡ Department of Neurosurgery, Johns Hopkins
University School of Medicine, The Johns
Hopkins Hospital, Baltimore, Maryland;
§
Department of Neurosurgery, Drexel
College of Medicine, Philadelphia, Pennsylvania; ¶ Marcus Neuroscience Institute,
Boca Raton Regional Hospital, Boca Raton, Florida; || Global Neurosciences Institute, Department of Neurosurgery,
Drexel University College of Medicine,
Philadelphia, Pennsylvania

Correspondence:
Chad R. Gordon, DO,
Division of Neuroplastic and
Reconstructive Surgery,
Department of Neurosurgery,
Johns Hopkins University School of
Medicine,
JHOC, 8th Floor,
601 N. Caroline St.,
Baltimore, MD 21287.
E-mail: cgordon@jhmi.edu
Received, July 5, 2018.
Accepted, January 29, 2019.
Published Online, February 7, 2019.

C Congress of Neurological Surgeons
2019.

This is an Open Access article distributed
under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs
licence (http://creativecommons.org/
licenses/by-nc-nd/4.0/), which permits
non-commercial reproduction and
distribution of the work, in any medium,
provided the original work is not altered
or transformed in any way, and that the
work is properly cited. For commercial
re-use, please contact
journals.permissions@oup.com

BACKGROUND: Implantable shunt devices are critical and life saving for hydrocephalus
patients. However, these devices are fraught with high complication rates including scalp
dehiscence, exposure, and extrusion. In fact, high shunt valve profiles are correlated with
increased complications compared to those with lower profiles. As such, we sought a new
method for integrating shunt valves for those challenging patients presenting with scalprelated complications.
OBJECTIVE: To safely implant and integrate a hydrocephalus shunt valve device within a
customized cranial implant, in an effort to limit its high-profile nature as a main contributor
to shunt failure and scalp breakdown, and at the same time, improve patient satisfaction
by preventing contour deformity.
METHODS: A 64-yr-old male presented with an extruding hydrocephalus shunt valve
and chronic, open scalp wound. The shunt valve was removed and temporary shunt
externalization was performed. He received 2 wk of culture-directed antibiotics. Next,
a contralateral craniectomy was performed allowing a new shunt valve system to be
implanted within a low-profile, customized cranial implant. All efforts were made, at the
patient’s request, to decrease the high-profile nature of the shunt valve contributing to his
most recent complication.
RESULTS: First-in-human implantation was performed without complication. Postoperative shunt identification and programming was uncomplicated. The high-profile nature
of the shunt valve was decreased by 87%. At 10 mo, the patient has experienced no complications and is extremely satisfied with his appearance.
CONCLUSION: This first-in-human experience suggests that a high-profile hydrocephalus
shunt device may be safely integrated within a customized cranial implant.
KEY WORDS: Hydrocephalus shunt, Cranioplasty, Cranial implant, Shunt complication, Implant extrusion, Scalp
wound, Ventriculoperitoneal shunt
Operative Neurosurgery 17:608–615, 2019

H

ydrocephalus shunting is one of the
most common procedures performed in
all types of neurosurgery. More importantly, implanted hydrocephalus shunts, and
their accompanying valves, are manufactured in
numerous designs/shapes with a common valve
thickness between 3 and 10 mm. Most devices
are constructed using a combination of rigid

ABBREVIATIONS: CAD/CAM, computer-assisted
design/manufacturing; CSF, cerebrospinal fluid
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plastic and/or silicone placed in the subgaleal
space external to the skull in close proximity to
the ventricle. However, although their material
may be modified in composition, all shunt
devices are designed for placement within the
head at a “nonanatomic” location fraught with
complication between the thin, mobile scalp
and the strong, immobile skull. Overall, it is
the nonanatomical placement of valve hardware,
combined with their rigid construction, which
may contribute to their high complication
rates approaching 40 to 60%. In fact, complication rates are even more staggering (around
70-80%) in those who have undergone at least
one previous shunt revision.1,2
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an admission to the neurological intensive care unit with
temporary external ventricular drainage. The duration of
external ventricular drainage often ranges from 7 to 14 d
and includes culture-directed intravenous antibiotics followed
by secondary insertion of a new internalized shunt device. As
such, for these complex patients who present with shunt valve
extrusion/exposure necessitating removal, most would agree that
every effort should be made at time of shunt valve replacement
to prevent the scalp-related complication from occurring
again.

METHODS
FIGURE 1. Preoperative photograph of inaugural patient presenting to neuroplastic surgery clinic with, left-sided scalp wound and extruding shunt valve.
One can appreciate the high-profile shunt’s visible deformity (represented by
dotted black line), as well as the exposed valve (red arrow).

Shunt-related complications requiring surgical revision are
categorized as either “catheter-related” (ie, proximal or distal
obstruction) or “scalp-related” (ie, extrusion through scalp,
infection, wound dehiscence, etc).3,4 Despite numerous strategies
for reducing infection, it remains the most common complication with an incidence approaching 30%.5,6 However, each case
of “infection” is different, since the true etiology may include
(1) bacterial contamination at time of placement, (2) systemic
seeding from blood-borne pathogens, or (3) primary scalp dehiscence/shunt extrusion leading to secondary infection. In other
words, infection may not be the sole cause of failure, depending
on which condition came first. For example, infection may result
from secondary contamination following scalp breakdown, and
thus, it is sometimes misclassified as “infection” and not as
“incisional dehiscence/scalp wound.” This sequela occurs from
excessive scalp tension over the nonanatomical, high-profile
device and long-standing pressure from underneath causing
localized ischemia and tissue necrosis.
For instance, the relentless pressure from underneath the scalp
leads to tissue necrosis in a manner quite similar to sacral pressure
ulcers commonly seen by plastic surgery. Essentially, the necrotic
wound begins at the deepest aspect—closest to the source, since its
etiology relates directly to pressure and is invisible to the human
eye. In the case of hydrocephalus, the rigid structure is the highprofile shunt valve causing an unbalanced pressure from within,
similar to the bony prominence causing the constant pressure in
the debilitated, bed-ridden patient. As such, the pressure-induced
tissue necrosis from the high-profile shunt valve device leads to
the unforeseen formation of an open scalp wound (Figure 1).
From there, the shunt hardware becomes exposed and bacterial
contamination/biofilm formation is unpreventable and equates to
eventual hardware removal.7,8
Unfortunately, for shunt-dependent patients with severe
hydrocephalus, shunt exposure is a major setback. It necessitates
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A 63-yr-old male presented with a complicated history including
obstructive hydrocephalus, cerebellar stroke, syringomyelia, and ArnoldChiari malformation (treated by decompression and complicated by
infected dural patch). His first ventriculoperitoneal shunt was placed
10 yr prior, and since then, had undergone 2 separate revision surgeries
for shunt malfunction. Two years later, he presented to us with a chronic,
open scalp wound. Further workup revealed that the open scalp wound
was related to hardware extrusion (Figure 1). The patient underwent
surgery for shunt hardware removal and insertion of temporary externalized ventricular drain. In addition, the scalp wound was excised
by neuroplastic surgery and closed with adjacent tissue transfer. The
patient remained in the hospital with external ventricular drainage while
receiving culture-directed intravenous antibiotics.
During this time, a customized cranial implant (InvisiShunt,
Longeviti Neuro Solutions, Hunt Valley, Maryland) was designed specifically to house the exact shunt valve type planned for future implantation by neurosurgery (M.L.). Computer-assisted design/manufacturing
(CAD/CAM) was performed in virtual fashion to allow the multidisciplinary team to coordinate exact locations with respect to contralateral
shunt placement, planned craniectomy boundaries, and incisional/scalp
flap exposure. Of note, the cranial implant was requested to be made
out of high-density polyethylene, so that its mechanical properties would
allow for intraoperative modification and flexibility as needed to better
accommodate the convex curvature of the cranium—as opposed to
a more rigid alloplastic material like poly-ether-ether-ketone or polymethyl-methacrylate. Of note, the upfront cost for this specific implant
was institutional-dependent based on prenegotiated terms with the
manufacturer. Furthermore, the cost of the implant is a fraction of the
cost of a redo shunt and hospitalization.
Following design and fabrication, the customized cranial implant was
shipped to our hospital in sterile packing. This process was managed
by the hospital. Data collection and review of this case were performed
under an active Institutional Review Board protocol. The patient was
informed preoperatively of the detailed plan and no additional consent
was required for the operation since the hydrocephalus shunt device
and customized cranial implant are both FDA approved; the patient
consented to publication of their photograph.
At 2 wk, the second-stage surgery was performed on the contralateral
side since the patient had communicating hydrocephalus, and in an effort
to avoid the previously contaminated field/scarred scalp (Video, Supplemental Digital Content). The borders of the limited craniectomy were
hand-drawn using a marking pen and template, as shown in Figure 2. Of
note, the size of the limited craniectomy was oval-shaped and measured
approximately 3.5 × 6.5 cm (Figure 3). The size limits of the craniectomy

VOLUME 17 | NUMBER 6 | DECEMBER 2019 | 609

GORDON ET AL

FIGURE 4. Intraoperative photograph of proximal catheter being placed via
navigational guidance.

FIGURE 2. Intraoperative photograph of customized cranial
implant made of high-density polyethylene. In particular, there is
an exact fit design incorporated within the customized implant to
accommodate the specific shunt valve system being selected by the
neurosurgeon.

FIGURE 5. Intraoperative photograph of high-profile shunt valve implanted
within customized cranial implant along right-sided temporoparietal location.
Titanium screws fixate the cranial implant along the periphery.

FIGURE 3. Intraoperative photograph of marking template being used to
identify exact burr hole locations on either end. Next, a craniotome is used
to complete the limited craniectomy.
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were determined based on length and width of the device. The proximal
catheter was placed uneventfully in the lateral ventricle using intraoperative guidance (Figure 4). The distal catheter was placed in the peritoneal
cavity using standard technique. Once both catheters were in proper
position, the customized cranial implant was inset within the limited
craniectomy defect and fixated with titanium screws along the periphery
(Figure 5). The high-profile shunt device was then integrated within the
implant, and the proximal catheter was passed through and connected.
The distal catheter was connected and positioned within a customized
groove at an angle less than 90 degrees. Following integration, the shunt
valve was measured before inset to be 8 mm tall. Following implantation within the customized cranial implant, its relative height was
reduced to just 1 mm, which left its edges just high enough to palpate
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FIGURE 6. Intraoperative photograph showing the re-draping and inset of a
pericranial-temporalis muscle flap over the inferior shunt valve/cranial implant
in preparation for final scalp closure.

FIGURE 8. Postoperative CT scan with 3-dimensional reconstruction
showing right-sided hydrocephalus shunt valve implantation within a
customized cranial implant. In particular, the high-density polyethylene
cranial implant is radiolucent and cannot be seen within the craniectomy site.

cranial implant has not interfered with any shunt programming
or valve localization. To date, his hydrocephalus has remained
well controlled. In particular, the overall height of his shunt
valve device was decreased by 87%, as compared to its previous
placement height which led to eventual extrusion (Figure 8).
Overall, there is a significant difference in shunt valve prominence
as compared to its previous placement, as shown in Figure 9.

DISCUSSION
FIGURE 7. Right-sided intraoperative photograph of the final cranial contour
following multilayered scalp closure. Of note, a single suture (red arrow) was
placed above the low-profile shunt valve for this inaugural case to assist with
postoperative device identification.

subcutaneously with one’s fingers. Proper function and shunt flow were
confirmed prior to flap inset, multilayered scalp closure, and closed
suction drain insertion (Figures 6 and 7).

RESULTS
The patient underwent an uneventful recovery. At 9 mo, the
patient has experienced no scalp wound complications and/or
pain in the area of the device. In particular, the surrounding
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Although shunt failure has been extensively studied, most
studies have focused on pediatric patients.9 With this in mind,
we present our experience with shunt-related scalp complications in the adult population. Furthermore, we present a new
approach to lower shunt device profiles, especially in those who
present with hardware extrusion and/or incisional scalp dehiscence. One well-described option is to shave down some cortical
bone in a shape that matches the device. However, this approach
is time consuming and only reduces the height by a maximum of
1 to 2 mm.10 As such, we chose to instead perform a limited,
full-thickness craniectomy in an effort to drastically lower the
shunt’s profile and to minimize risk for repeat extrusion. Of note,
this technique has been performed successfully in other similar
settings where implants are of high profile, such as deep brain
stimulators, plates, and cortical stimulators.
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FIGURE 9. Postoperative CT scans on patient following first and second hydrocephalus surgery using the
exact same high-profile shunt device. One can appreciate, on frontal view, the significant difference in
projection with (right image) and without (left image) implantation within a customized cranial implant.

Approximately 40 000 new shunts are placed annually for
hydrocephalus management. Unfortunately, shunt replacement
and shunt removal are quite frequent at a rate of 43% and 7%,
respectively.5 In fact, Reddy et al9 investigated predisposing risk
factors for all shunt-related complications in 1015 patients and
found the rate of revision shunt surgery to be close to 1 out
of every 2 patients (46%). Furthermore, the history of previous
shunt revision surgery increases the odds of needing subsequent
surgery by 9-fold, and when revision surgery is required, it occurs
most often within the first 6 mo. Interestingly, they found that
“infection-related complications” are the most common cause
for re-admission in shunted hydrocephalus patients.9 However,
overall shunt infections are more likely secondary to initial
intention rather than scalp breakdown, and so further investigation is needed to estimate the incidence of both scenarios.
Given the staggering rate (46-48%) for shunt revision in
one’s lifetime, novel or unconventional strategies by which these
complications could be minimized and/or avoided altogether are
worthy of consideration.4,11 In looking at the current design of
shunts, our team noted a common design characteristic being the
high-profile nature of the shunt valve, which is placed between the
rigid skull and supple scalp. In our opinion, devastating complications such as scalp wounds and implant exposure/infection
are foreseeable when using high-profile, extra-anatomical shunt
valves, simply because these devices place unsafe pressure on
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the deep scalp, where its vascular perfusion is most affected
(ie, dermal-subdermal plexus). This hypothesis is confirmed by
other studies that show that high-profile shunts, as opposed to
low-profile shunts, have a greater tendency to require removal
secondary to extrusion/infection.7,8
With regard to shunt re-implantation for those patients with
history of scalp-related complications, our preference is to place all
hardware (shunt tubing and valve) opposite the side of the original
infection, if possible, in cases of communicating hydrocephalus.
Either way, we strive to relocate all replaced hardware in an area
most distal from the previous compromised scalp. Thus, when
bilateral ventricular dilation or communicating hydrocephalus
is noted, we use the contralateral side. This strategy serves 2
benefits. First, it helps avoid the previously contaminated soft
tissue pocket. Second, it removes the permanent shunt from the
zone of injury (ie, scar tissue), thereby allowing us to place the
new hardware under healthy scalp with normal perfusion and
thickness.
In this particular instance, the main precipitating factor
was the high-profile, rigid shunt device and its pressure on
the overlying scalp. Therefore, to address this, we performed a
small-sized craniectomy using a burr and craniotome (by way of
a predesigned marking template supplied by the manufacturer).
Attempting to drill a partial-thickness cranial defect to mirror the
necessary shunt device would have been quite challenging given
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its 3-dimensional shape. Furthermore, a partial-thickness defect
may have only reduced the overall thickness by 1 to 2 mm.12 As
such, following a prolonged discussion with the patient in regard
to the novelty of this approach, we decided to use a low-profile
customized implant to reduce the valve’s height by 87%, and
at the same time, eliminate all concern for shunt migration by
providing a “key-and-lock” type fit (Figure 5).
While the hydrocephalus shunt is credited with saving and
improving millions of lives worldwide each year, there are
also challenging associated complications. Therefore, examination of shunt systems in order to help minimize co-existing
variables, which lead to extraordinarily high revision rates,
may be warranted. The proposed method of reducing shunt
valve prominence avoids compression of the scalp’s vital blood
supply. In addition, the use of a customized cranial implant
is attractive as a “manufacturer-agnostic” alternative, meaning
that the CAD/CAM process can shape it for all shunt valve
types.
Regardless, we predict that design changes such as these
may serve to significantly decrease the need for shunt-related
revision surgery and the cumulative effects of shunt revision
surgery/interval hospital admissions. It is estimated that the
average cost of a cerebrospinal fluid (CSF) catheter-related
infection in the United States is approximately $50 000.
Therefore, it is imperative to consider these consequences when
assessing the upfront cost of customized implant materials
designed to prevent revision surgery.6, 13 Another advantage (well
appreciated by this patient) in reducing valve prominence is the
minimization of visible deformity along the scalp when compared
with its usual placement (Figure 10). Of note, this is increasingly
important in patients with male-pattern balding and/or short
hair, who hope to avoid the social stigma accompanying their
neurological condition and/or the fact that they have undergone
previous brain surgery.
Unquestionably, shunt-related complications are devastating to
all patients regardless of age, ranging from simple adjustment to
definitive removal. Although these complications are complex and
multifactorial, the scalp-related variables play a major factor in
cases of extrusion/failure and therefore, with this advance, could
be prevented by way of a low-profile inset. As such, the ability to
securely house shunt valves within the confines of a craniectomy
defect (ie, intercranial space) by taking advantage of underutilized space within a cranial implant provides many newfound
advantages (Figure 11).14-16 This includes offering our patients
an option for an improved appearance with enhanced contour,
while concurrently decreasing detrimental pressure and relative
ischemia onto their overlying scalp (Figures 8 and 9).
Limitations
Of note, there are several limitations to this preliminary report.
First, it is limited to just a single patient. However, at the time
of this submission, a total of 8 cases have been performed with
no complications to date as part of a larger multicenter study
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FIGURE 10. Frontal view of inaugural patient at 1 mo following
right-sided hydrocephalus shunt valve implantation within a
customized cranial implant. In addition, there is no visible contour
deformity other than a small palpable bump.

involving various neurosurgical groups. Second, a relatively short
follow-up time of 9 mo may not capture eventual complications
which could develop at a later date, and thus a large series of
successful implantations is unquestionably warranted. However,
given the variables which we modified to prevent future “scalprelated” complications, in combination with data showing that
shunt-related complications most often occur within the first 6
mo, we feel obliged to share our initial experience with others
challenged by shunt valve extrusions/complicated scalp wounds
and the limited options which currently exist.4
Advantages and Disadvantages
In parallel, there are several important advantages and disadvantages with this first-in-human experience. First, the advantages
of integrating hardware within a customized cranial implant is
an advance and may serve as a platform for all hydrocephalusrelated neurotechnologies, including flow meters to detect shunt
malfunction and/or pressure monitors, to diagnose elevated
intracranial pressures. Of course, as this research progresses,
one could envision implanting some of these technologies all
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FIGURE 11. Artistic illustration of a novel concept to utilize one’s valuable intercranial space, following limited craniectomy, to offer neurosurgical patients an improved method of implanting low-profile devices for A, disease types such as malignant brain tumors (ie, local chemotherapy
delivery), B, hydrocephalus (ie, combined shunt/pressure monitor), and C, medicine-resistant epilepsy (ie, neuromodulation therapy). Used
with permission, all rights reserved.

at the same time. In contrast, the obvious disadvantage is the
craniectomy which is required, as opposed to a standard burr hole
for proximal catheter insertion, which is greater in dimension.
Thus, there is additional risk for related complications such
as durotomy, CSF leak, and epidural hematoma. However, in
an instance such as the one presented here—in a patient with
previous shunt hardware extrusion—the risk-to-benefit ratio of
providing a low-profile cranial implant to prevent further scalprelated complications vs the accompanying craniectomy risks is
well justified. As a result, this approach should be considered
most applicable for cases with recurrent shunt failure and with
vulnerable scalp.
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CONCLUSION
The prominence of hydrocephalus shunt devices under the
scalp by way of standard implantation is a contributing factor
for soft tissue complications associated with hydrocephalus.
Integration of the high-profile shunt valve within the confines of
a customized cranial implant appears to be both safe and reliable.
This first-in-human experience provides a pragmatic strategy
for (1) minimizing risk (ie, open scalp wounds/extrusion), (2)
providing a novel strategy to improve long-term outcomes, (3)
increasing the potential to optimize patient satisfaction and
appearance, and (4) supplying a viable platform for exciting future
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neurotechnology advances related to hydrocephalus such as flow
meters and pressure monitors.
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